Session I - Latin American Pertussis Project

Welcome remarks and Sabin Vaccine Institute partner perspective - Stacey Knobler

Pan American Health Organization partner perspective - Ana Elena Chevez

U.S. Centers for Disease Control and Prevention partner perspective - M. Lucia Tondella

Remarks from Ministry of Health, Argentina - Cristián Biscayart

Session II – Panel discussions: updates on LAPP-country epidemiology and impact of LAPP-informed surveillance recommendations

The impact of LAPP capacity-building, training, and research on pertussis vaccination and control strategies:

Session III – Pertussis epidemiology and impact of control strategies in Latin America and globally

Overview of pertussis in Latin America - Ana Elena Chevez

Epidemiology and Advances in the diagnosis of pertussis in Perú - Faviola Valdivia Guerrero

Maternal vaccination in Argentina: Tdap vaccine effectiveness during pregnancy - Viviana Romanin

Maternal and infant pertussis vaccination: finding the sweet spot - Helen Petousis-Harris

Session IV– Molecular characterization and phenotypic analysis of Bordetella species

Vaccine immunogen deficiency in the United States - Lucia Pawloski

Research and genetic characterization of the circulating strains of Bordetella pertussis in Brazil. Are there any new variants in the country? - Daniela Leite

Pertactin-negative Bordetella pertussis strains are rarely detected in Argentina a country that use whole cell vaccine for primary doses - Daniela Hozbor

Antibiotic susceptibility - Pam Cassiday

Session V – Panel discussion: the future of pertussis vaccine strategies and research in Latin America

Discussion topics:

  • strategies and new developments to control pertussis wP-aP boosting, maternal immunization, vaccine reformulation & novel vaccines
  • application and capacity for culture-independent genomics
  • needs/efforts to improve disease surveillance 

Summary and closing remarks